Dihyropyrimidine dehydrogenase (DPYD) Out Source from Mayo Clinic at Chughtai Lab

Dihyropyrimidine dehydrogenase (DPYD) Out Source from Mayo Clinic at Chughtai Lab

The Dihyropyrimidine dehydrogenase (DPYD) Out Source from Mayo Clinic at Chughtai Lab is a highly specialized pharmacogenomic test designed to identify genetic variants in the DPYD gene. This gene encodes the dihydropyrimidine dehydrogenase (DPD) enzyme, which is responsible for metabolizing fluoropyrimidine chemotherapeutic agents, such as 5-Fluorouracil (5-FU) and its oral prodrug, Capecitabine. These medications are widely prescribed for treating various solid tumors, including colorectal, breast, gastric, and head and neck cancers. However, individuals with a deficiency in the DPD enzyme are at an exceptionally high risk of experiencing severe, potentially life-threatening toxicities when exposed to standard doses of these drugs. By utilizing advanced molecular testing methodologies at Mayo Clinic Laboratories, this diagnostic service provides critical genetic insights that enable oncologists to personalize chemotherapy regimens, adjust dosages, or select alternative therapeutic agents to ensure patient safety.

The clinical importance of the Dihyropyrimidine dehydrogenase (DPYD) Out Source from Mayo Clinic cannot be overstated. Standard chemotherapy dosing assumes normal metabolic capacity; however, patients with partial or complete DPD deficiency cannot clear fluoropyrimidines efficiently. This leads to a rapid accumulation of the active drug in the systemic circulation, causing profound bone marrow suppression, severe gastrointestinal toxicity, and susceptibility to life-threatening infections. By identifying specific high-risk DPYD variants before the initiation of treatment, this test serves as a vital safety screen. The diagnostic value lies in its ability to categorize patients into normal, intermediate, or poor metabolizers, allowing for proactive clinical decisions that significantly reduce the incidence of severe adverse drug reactions while maintaining oncological efficacy.

Clinical Procedure: What to Expect

Patient Preparation

To ensure the integrity of the sample and the accuracy of the genetic analysis, patients must adhere to specific preparation guidelines before undergoing the blood draw for the Dihyropyrimidine dehydrogenase (DPYD) Out Source from Mayo Clinic:

• No Fasting Required: Patients do not need to fast before this test. Dietary intake does not affect genomic DNA extraction or genetic sequencing results.
• Clinical History Documentation: It is essential to provide a complete clinical history, including the type of cancer diagnosed, the planned chemotherapy regimen (e.g., 5-FU or Capecitabine), and any history of prior adverse reactions to chemotherapy.
• Medication History: Inform the healthcare provider of all current medications, over-the-counter drugs, and herbal supplements. While they do not alter genetic results, they are important for overall clinical assessment.
• Blood Transfusion History: Patients who have received a whole blood transfusion within the last 30 days must inform the laboratory, as donor DNA can temporarily interfere with the genetic analysis.

During the Procedure

The sample collection process for the Dihyropyrimidine dehydrogenase (DPYD) Out Source from Mayo Clinic is straightforward and follows strict clinical protocols to maintain sample viability for international transport:

• Venipuncture: A certified phlebotomist at Chughtai Lab will perform a standard venipuncture, typically drawing blood from a vein in the inner elbow.
• Sample Collection Tube: The blood sample is collected in a lavender-top (EDTA) tube, which is essential for preserving genomic DNA.
• Strict Cold Chain Logistics: Because this is an outsourced test, Chughtai Lab immediately processes and prepares the specimen according to Mayo Clinic Laboratories’ stringent shipping specifications, maintaining a controlled cold chain to preserve sample stability during transit.
• Duration: The blood draw itself takes less than five minutes and is associated with minimal discomfort, similar to a mild pinch.
• Safety Considerations: Standard sterile techniques are strictly observed to prevent infection, and the risk of complications is extremely low, limited to minor bruising at the puncture site.

When is a Dihyropyrimidine dehydrogenase (DPYD) Out Source from Mayo Clinic Performed?

Pre-Chemotherapy Screening for Colorectal Cancer Patients

Oncologists frequently request this test before initiating 5-Fluorouracil or Capecitabine-based chemotherapy regimens for patients diagnosed with colorectal cancer. Identifying DPYD variants beforehand allows clinicians to adjust the starting dose or choose alternative therapies, preventing severe toxicities such as neutropenic fever, severe diarrhea, and hand-foot syndrome.

Evaluation Prior to Breast Cancer Treatment

For breast cancer patients scheduled to receive combination chemotherapy regimens containing fluoropyrimidines, pre-treatment genetic testing is highly recommended. The test helps identify individuals who may experience severe myelosuppression, enabling the medical team to customize the treatment plan to safeguard the patient’s immune system and overall health.

Unexplained Severe Toxicity During Active Chemotherapy

If a patient undergoing treatment with 5-FU or Capecitabine experiences unexpectedly severe, early-onset toxicities—such as grade 3 or 4 mucositis, profound leukopenia, or intractable diarrhea—the physician will order this test. This helps determine if an underlying genetic DPD deficiency is the cause of the adverse reaction, guiding immediate dose modifications or treatment cessation.

Pre-Treatment Assessment for Gastrointestinal Malignancies

Patients diagnosed with gastric, pancreatic, or esophageal cancers who are candidates for fluoropyrimidine therapy undergo this test to establish their metabolic baseline. Because these aggressive cancers require timely and effective treatment, knowing the patient’s DPYD status ensures that chemotherapy can be administered safely without causing catastrophic treatment interruptions due to toxicity.

Pharmacogenomic Profiling for Personalized Oncology

As part of a comprehensive personalized medicine strategy, oncologists utilize this test to profile patients who have a family history of severe chemotherapy intolerance. This proactive approach ensures that genetic predispositions to drug toxicity are identified early, optimizing therapeutic outcomes and minimizing the risk of treatment-related morbidity.

What Does a Dihyropyrimidine dehydrogenase (DPYD) Out Source from Mayo Clinic Detect?

The Dihyropyrimidine dehydrogenase (DPYD) Out Source from Mayo Clinic is designed to detect specific genetic variations that correlate with reduced DPD enzyme activity. The test identifies several key clinically actionable findings, including:

• DPYD*2A (c.1905+1G>A) Variant: The most well-characterized mutation associated with profound DPD deficiency and a high risk of life-threatening toxicity.
• DPYD*13 (c.1679T>G) Variant: A rare but highly significant variant that results in near-complete loss of enzyme activity.
• DPYD c.2846A>T Variant: A missense mutation associated with moderately to severely reduced DPD enzyme function.
• DPYD c.1129-5923C>G (HapB3) Variant: A deep intronic variant associated with decreased DPD activity and increased risk of toxicity.
• Heterozygous Genotype: Indicates the presence of one normal allele and one mutated allele, resulting in partial DPD deficiency.
• Homozygous Genotype: Indicates the presence of two mutated alleles, resulting in complete or near-complete DPD deficiency.
• Wild-Type Genotype: Confirms the absence of the tested high-risk variants, suggesting normal DPD enzyme activity.
• DPD Activity Score: A calculated score based on the detected genotype used to guide clinical dosing recommendations.
• Risk of Severe Myelosuppression: Identification of genetic predisposition to profound bone marrow depression.
• Risk of Severe Mucositis: Predisposition to painful inflammation and ulceration of the mucous membranes lining the digestive tract.
• Risk of Severe Enterocolitis: Genetic susceptibility to life-threatening inflammation of the digestive tract.
• Altered Drug Clearance: Assessment of the body’s reduced ability to eliminate fluoropyrimidine metabolites.
• Potential for Neurotoxicity: Increased risk of central nervous system toxicity associated with high systemic drug levels.
• Need for Alternative Chemotherapy: Clear indication when non-fluoropyrimidine regimens should be considered.
• Dose Reduction Requirements: Guidance on the percentage of dose reduction needed for intermediate metabolizers.

Turnaround Time and Report Access at Chughtai Lab

Because the Dihyropyrimidine dehydrogenase (DPYD) Out Source from Mayo Clinic is a highly specialized molecular test outsourced to Mayo Clinic Laboratories in the United States, the turnaround time is typically 10 to 14 working days. This timeframe accounts for international cold chain logistics, DNA extraction, high-throughput genetic sequencing, and expert clinical interpretation. Once the results are finalized by Mayo Clinic, they are integrated into Chughtai Lab’s secure database. Patients and their referring oncologists can access the detailed reports online through the Chughtai Lab website portal, the dedicated mobile application, or via WhatsApp. Physical copies of the reports can also be collected from any Chughtai Lab diagnostic center across Pakistan.

Dihyropyrimidine dehydrogenase (DPYD) Out Source from Mayo Clinic Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
DPYD*2A (c.1905+1G>A)	Negative (Wild-type)	Positive (Heterozygous or Homozygous mutation)
DPYD*13 (c.1679T>G)	Negative (Wild-type)	Positive (Heterozygous or Homozygous mutation)
DPYD c.2846A>T	Negative (Wild-type)	Positive (Heterozygous or Homozygous mutation)
DPYD c.1129-5923C>G	Negative (Wild-type)	Positive (Heterozygous or Homozygous mutation)
DPD Enzyme Activity Score	Activity Score: 2.0 (Normal)	Activity Score: 1.0 to 1.5 (Partial); < 1.0 (Profound)
Fluoropyrimidine Toxicity Risk	Standard Risk	High to Extremely High Risk of Grade 3-4 Toxicity
Chemotherapy Dosing Guidance	Standard Dosing (100% dose)	Dose Reduction (25%-50%) or Avoid Fluoropyrimidines

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Dihyropyrimidine dehydrogenase (DPYD) Out Source from Mayo Clinic?

• Partnership with Mayo Clinic Laboratories: Chughtai Lab facilitates direct access to world-class diagnostic testing from Mayo Clinic, ensuring unparalleled accuracy and clinical expertise.
• Strict Cold Chain Maintenance: The laboratory utilizes advanced temperature-controlled logistics to ensure that specimens remain stable and viable during international transport.
• ISO 15189 Certified Facilities: Chughtai Lab operates under stringent international quality control standards, ensuring reliable sample handling and processing.
• Convenient Online Report Access: Patients and oncologists can easily view, download, and share reports via the Chughtai Lab portal, mobile app, or WhatsApp.
• Nationwide Network: With collection centers across Pakistan, patients can easily have their samples collected close to home.
• Expert Pathologist Oversight: Local pathologists work in coordination with international reference laboratories to ensure seamless communication of critical results.
• Home Sample Collection Services: Chughtai Lab offers convenient home sample collection, allowing patients to undergo testing in the comfort of their homes.
• Patient-Centered Care: Dedicated support teams are available to assist patients with scheduling, sample requirements, and report retrieval.